AlphAIalphai — Financial news for AI agents
businessupturn.comAUG 33 min read$GSK

GSK Pharma Q1 Results: Net profit rises 16% YoY to Rs 237 crore, revenue jumps 17%

GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) reported Q1 FY27 results for the quarter ended June 2026. Net profit rose 15.7% YoY to ₹237.1 crore. Revenue from operations increased 16.6% to ₹938 crore. EBITDA grew 25.8% YoY to ₹444.3 crore, with EBITDA margin expanding to 47.35% from 43.86% a year earlier.

Original reporting
businessupturn.com
Published Aug 3, 2026, 10:27 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 2:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
GSK Pharma Q1 Results: Net profit rises 16% YoY to Rs 237 crore, revenue jumps 17% — source image
Source · businessupturn.com
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

Margin expansion (EBITDA margin rising to 47.35% from 43.86%) suggests improved operating efficiency alongside sales growth, which can influence near-term valuation and estimate revisions.

02

Market read

Traders can use the reported Q1 profit and margin expansion as a fresh fundamental input for short-term positioning, though no forward guidance is provided.

03

What to watch

The article does not mention cash flow, one-offs, tax effects, or management outlook, which are often key for sustaining the earnings multiple.

Relevance 7/10Novelty 6/10Timing: Q1 results reported for quarter ended June 2026, likely driving immediate earnings positioning.

Background

The piece summarizes GSK Pharma’s Q1 FY27 financial performance, focusing on profit, revenue, EBITDA, and margin changes versus the prior year.

Company-level read

Ticker impact

$GSKBullishMedium confidence
Context

GSK Pharma reported Q1 FY27 net profit up 15.7% YoY to Rs 237.1 crore and revenue up 16.6% to Rs 938 crore.

Expected impact

Mildly positive bias for the next few sessions as traders digest the profit and margin beat versus prior-year levels.

Evidence & confidence

Reported YoY growth in net profit, revenue, EBITDA, and EBITDA margin expansion are concrete fundamentals that typically move earnings expectations, though no guidance or consensus comparison is provided.

Market effects

Sector

Positive read-through for Indian pharma profitability trends if investors extrapolate margin improvement as operational efficiency.

Regional

Could modestly support broader India pharma sentiment on earnings season, but the article provides no peer or sector-wide data.

Global

Limited, since the disclosure is company-specific and lacks cross-border guidance or regulatory developments.

Counterpoint

What could challenge this read

YoY comparisons can look strong due to base effects; without sequential trends, guidance, or segment detail, the market may discount durability.

Key entities

  • company
    GSK Pharma

    GlaxoSmithKline Pharmaceuticals Ltd, reported Q1 FY27 net profit, revenue, EBITDA, and margin changes versus the prior year.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 3
$GSKMedAI 8/10

GSK Pharma Q1 Net Profit Jumps 16% To ₹237 Crore

GlaxoSmithKline Pharmaceuticals reported Q1 FY2026-27 net profit of ₹237.1 crore, up 15.7% from ₹205 crore a year earlier. Revenue from operations rose 16.6% to ₹938 crore. EBITDA increased 25.8% to ₹444.3 crore, lifting EBITDA margin to 47.35%. The company cited growth across medicines, respiratory, vaccines, and oncology, and noted plans for Blenrep and marketing authorization for Arexvy.

whalesbook.com4 min
AUG 3
$GSKMedAI 8/10

GSK Pharma Q1 profit rises 16% as general medicines, vaccines drive growth

GSK plc subsidiary GSK Pharma reported June-quarter FY27 net profit of ₹237.1 crore, up 16% from ₹205 crore a year earlier. Revenue from operations rose 16.6% to ₹938 crore. EBITDA increased 25.8% to ₹444.3 crore and margin to 47.35%. Growth was driven by general medicines and vaccines; oncology and pipeline launches were also cited.

cnbctv18.com5 min
AUG 3
$GSKMed

GSK India Q1FY27 PAT rises 24% to ₹253 crore on portfolio strength

GlaxoSmithKline Pharmaceuticals India reported Q1FY27 standalone PAT up 24% to ₹253 crore and revenue up 15% to ₹924 crore, ended June 30, 2026, citing portfolio transformation and base effects. Consolidated net profit rose 15.7% to ₹2,371.8 crore and revenue grew 16.5% to ₹9,384.4 crore. The board approved results Aug 3, 2026 and announced leadership changes.

scanx.trade6 min
AUG 3
$GSKMed

GSK Pharmaceuticals: Q1 FY27 Results Show Slight Revenue Dip, Management Changes

GlaxoSmithKline Pharmaceuticals Limited reported Q1 FY27 (ended June 30, 2026) unaudited results. Standalone revenue from operations was ₹92,442 lakhs and profit after tax ₹25,333 lakhs, with EPS ₹14.95. Consolidated revenue from operations was ₹93,844 lakhs and PAT ₹23,718 lakhs, EPS ₹14.00. The board noted a non-executive director resignation and reappointed Bhushan Akshikar as managing director for two years.

investywise.com4 min
JUL 31
$VTRSMed

Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals

The healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac

rttnews.com7 min
GSK Pharma Q1 Results: Net profit rises 16% YoY to Rs 237 crore, revenue jumps 17% — alphai